Biocartis

Biocartis is an innovative molecular diagnostics company committed to revolutionizing molecular testing with its unique proprietary Idylla™ Platform.

Biocartis is an innovative commercial stage molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. The Company’s proprietary MDx Idylla™ platform is a fully automated, real time system which offers accurate, highly-reliable molecular information from any biological sample in virtually any setting. Idylla™ addresses the growing demand for personalized medicine by allowing fast and effective treatment selection and treatment progress monitoring. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest and largest growing segments of the US$5 billion MDx market1 which is expected to grow to approximately US$8 billion in 2018.*

Biocartis employs approximately 300 people and is headquartered in Mechelen, Belgium. Further information can be found at: www.biocartis.com

* http://www.alliedmarketresearch.com/ivd-in-vitro-diagnostics-market

14/11/2025

𝗚𝗿𝗲𝗮𝘁 𝗳𝗶𝗿𝘀𝘁 𝗱𝗮𝘆 𝗮𝘁 ! 𝗧𝗵𝗮𝗻𝗸𝘀 𝘁𝗼 𝗲𝘃𝗲𝗿𝘆𝗼𝗻𝗲 𝘄𝗵𝗼 𝘀𝘁𝗼𝗽𝗽𝗲𝗱 𝗯𝘆!
Come meet us at 𝗯𝗼𝗼𝘁𝗵 𝟰𝟮𝟭 and discover how Idylla™ can deliver your fully automated molecular biomarker results in 𝗼𝗻𝗹𝘆 𝟯 𝗵𝗼𝘂𝗿𝘀!
🗓️ 11-15 November |📍Boston, MA, US

👉 𝗕𝗼𝗼𝗸 𝘆𝗼𝘂𝗿 𝗺𝗲𝗲𝘁𝗶𝗻𝗴 https://lnkd.in/eVyaZ8qA
👉 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿 𝗜𝗱𝘆𝗹𝗹𝗮™ https://lnkd.in/eRx8fbYs

We can’t wait to connect with you! 👋

14/11/2025

𝟭𝟬𝘁𝗵 𝗮𝗻𝗻𝗶𝘃𝗲𝗿𝘀𝗮𝗿𝘆 𝗼𝗳 𝗜𝗱𝘆𝗹𝗹𝗮™ 𝗶𝗻 𝗦𝗽𝗮𝗶𝗻 🎉
This November marks a decade since the first Idylla™ Platform was installed in Spain, marking the start of a new era in molecular diagnostics: 𝗳𝘂𝗹𝗹𝘆 𝗮𝘂𝘁𝗼𝗺𝗮𝘁𝗲𝗱, 𝗳𝗮𝘀𝘁 𝗮𝗻𝗱 𝘀𝘂𝗶𝘁𝗮𝗯𝗹𝗲 𝗳𝗼𝗿 𝗮𝗻𝘆 𝗹𝗮𝗯. Today, 𝗺𝗼𝗿𝗲 𝘁𝗵𝗮𝗻 𝟭𝟬𝟬 𝗰𝗲𝗻𝘁𝗲𝗿𝘀 𝗶𝗻 𝗦𝗽𝗮𝗶𝗻 rely on Idylla™ to deliver reliable molecular biomarker results in record time ⏱️

10 years on, we’re proud of the impact Idylla™ has made in Spain and remain committed to making precision medicine accessible to patients 𝗮𝗿𝗼𝘂𝗻𝗱 𝘁𝗵𝗲 𝘄𝗼𝗿𝗹𝗱 🌍
👏 𝗔 𝗵𝗲𝗮𝗿𝘁𝗳𝗲𝗹𝘁 𝘁𝗵𝗮𝗻𝗸 𝘆𝗼𝘂 𝘁𝗼 𝗮𝗹𝗹 𝘁𝗵𝗲 𝘁𝗲𝗰𝗵𝗻𝗶𝗰𝗶𝗮𝗻𝘀, 𝗯𝗶𝗼𝗹𝗼𝗴𝗶𝘀𝘁𝘀, 𝗽𝗮𝘁𝗵𝗼𝗹𝗼𝗴𝗶𝘀𝘁𝘀 𝗮𝗻𝗱 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗽𝗿𝗼𝗳𝗲𝘀𝘀𝗶𝗼𝗻𝗮𝗹𝘀 𝘄𝗵𝗼 𝗵𝗲𝗹𝗽 𝗺𝗮𝗸𝗲 𝘁𝗵𝗶𝘀 𝘃𝗶𝘀𝗶𝗼𝗻 𝗮 𝗿𝗲𝗮𝗹𝗶𝘁𝘆 𝗲𝘃𝗲𝗿𝘆 𝗱𝗮𝘆!

Curious what Idylla™ could mean for you and your lab?
𝗟𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲👉 https://lnkd.in/gh9nKbMA
_____________________________________________
𝟭𝟬.𝗼 𝗮𝗻𝗶𝘃𝗲𝗿𝘀𝗮𝗿𝗶𝗼 𝗱𝗲 𝗜𝗱𝘆𝗹𝗹𝗮™ 𝗲𝗻 𝗘𝘀𝗽𝗮𝗻𝗮 🎉
Este noviembre se cumplen diez años desde la instalación de la primera plataforma Idylla™ en España, lo que marcó el inicio de una nueva era en el diagnóstico molecular: 𝘁𝗼𝘁𝗮𝗹𝗺𝗲𝗻𝘁𝗲 𝗮𝘂𝘁𝗼𝗺𝗮𝘁𝗶𝘇𝗮𝗱𝗮, 𝗿𝗮𝗽𝗶𝗱𝗮 𝘆 𝗮𝗽𝘁𝗮 𝗽𝗮𝗿𝗮 𝗰𝘂𝗮𝗹𝗾𝘂𝗶𝗲𝗿 𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗼𝗿𝗶𝗼. Hoy, 𝗺𝗮𝘀 𝗱𝗲 𝟭𝟬𝟬 𝗰𝗲𝗻𝘁𝗿𝗼𝘀 𝗲𝗻 𝗘𝘀𝗽𝗮𝗻𝗮 confían en Idylla™ para obtener resultados fiables de biomarcadores moleculares en tiempo récord ⏱️

Tras 10 años, nos enorgullece el impacto que Idylla™ ha tenido en España y mantenemos nuestro compromiso de hacer que la medicina de precisión sea accesible a pacientes de 𝘁𝗼𝗱𝗼 𝗲𝗹 𝗺𝘂𝗻𝗱𝗼 🌍
👏 Un sincero agradecimiento a todos los técnicos/as, biólogos/as, patólogos/as y profesionales sanitarios que hacen posible esta visión cada día!

¿Quieres saber qué puede significar Idylla™ para ti y tu laboratorio?
𝗗𝗲𝘀𝗰𝘂𝗯𝗿𝗲 𝗺𝗮𝘀 👉 https://lnkd.in/gh9nKbMA

13/11/2025

🎉 𝗖𝗼𝗻𝗴𝗿𝗮𝘁𝘂𝗹𝗮𝘁𝗶𝗼𝗻𝘀 𝘁𝗼 𝗗𝗿. 𝗟𝗲𝗼𝗻𝗶𝗲 𝗪𝗵𝗲𝗲𝗹𝗱𝗼𝗻 𝗮𝗻𝗱 𝗵𝗲𝗿 𝘁𝗲𝗮𝗺!
The paper "𝘜𝘴𝘦 𝘰𝘧 𝘵𝘩𝘦 𝘉𝘪𝘰𝘤𝘢𝘳𝘵𝘪𝘴 𝘐𝘥𝘺𝘭𝘭𝘢™ 𝘗𝘭𝘢𝘵𝘧𝘰𝘳𝘮 𝘧𝘰𝘳 𝘵𝘩𝘦 𝘋𝘦𝘵𝘦𝘤𝘵𝘪𝘰𝘯 𝘰𝘧 𝘌𝘱𝘪𝘥𝘦𝘳𝘮𝘢𝘭 𝘎𝘳𝘰𝘸𝘵𝘩 𝘍𝘢𝘤𝘵𝘰𝘳 𝘙𝘦𝘤𝘦𝘱𝘵𝘰𝘳, 𝘉𝘙𝘈𝘍 𝘢𝘯𝘥 𝘒𝘙𝘈𝘚 𝘗𝘳𝘰𝘵𝘰-𝘖𝘯𝘤𝘰𝘨𝘦𝘯𝘦 𝘔𝘶𝘵𝘢𝘵𝘪𝘰𝘯𝘴 𝘪𝘯 𝘓𝘪𝘲𝘶𝘪𝘥-𝘉𝘢𝘴𝘦𝘥 𝘊𝘺𝘵𝘰𝘭𝘰𝘨𝘺 𝘚𝘱𝘦𝘤𝘪𝘮𝘦𝘯𝘴 𝘧𝘳𝘰𝘮 𝘗𝘢𝘵𝘪𝘦𝘯𝘵𝘴 𝘸𝘪𝘵𝘩 𝘕𝘰𝘯-𝘚𝘮𝘢𝘭𝘭 𝘊𝘦𝘭𝘭 𝘓𝘶𝘯𝘨 𝘊𝘢𝘳𝘤𝘪𝘯𝘰𝘮𝘢 𝘢𝘯𝘥 𝘗𝘢𝘯𝘤𝘳𝘦𝘢𝘵𝘪𝘤 𝘈𝘥𝘦𝘯𝘰𝘤𝘢𝘳𝘤𝘪𝘯𝘰𝘮𝘢" (Wheeldon et al., 2022) has been selected as 𝗘𝗱𝗶𝘁𝗼𝗿'𝘀 𝗖𝗵𝗼𝗶𝗰𝗲 𝗔𝗿𝘁𝗶𝗰𝗹𝗲 in the Journal of Molecular Pathology MDPI.
👏 Join us in congratulating the team on this remarkable achievement!

The study describes the use of the 𝗜𝗱𝘆𝗹𝗹𝗮™ 𝗣𝗹𝗮𝘁𝗳𝗼𝗿𝗺 to detect 𝗘𝗚𝗙𝗥, 𝗞𝗥𝗔𝗦, 𝗮𝗻𝗱 𝗕𝗥𝗔𝗙 mutations directly from liquid-based cytology (LBC) samples from patients with NSCLC and PDAC.
➡️ These findings support the use of Idylla™ for 𝗳𝗮𝘀𝘁, 𝗮𝗰𝗰𝘂𝗿𝗮𝘁𝗲 mutation testing directly on 𝗰𝘆𝘁𝗼𝗹𝗼𝗴𝘆 𝘀𝗽𝗲𝗰𝗶𝗺𝗲𝗻𝘀, enabling faster access to actionable molecular results.
📖 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗽𝘂𝗯𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻: http://www.mdpi.com/2673-5261/3/2/10
🔍 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿 𝗜𝗱𝘆𝗹𝗹𝗮™: https://www.biocartis.com/en/meet-idylla

Idylla™ EGFR, KRAS and BRAF Mutation Assays are for Research Use Only (RUO), not for use in diagnostic procedures.

Wheeldon, L., et al. (2022). Use of the Biocartis Idylla™ Platform for the Detection of Epidermal Growth Factor Receptor, BRAF and KRAS Proto-Oncogene Mutations in Liquid-Based Cytology Specimens from Patients with Non-Small Cell Lung Carcinoma and Pancreatic Adenocarcinoma. Journal of Molecular Pathology, 3(2), 104-114. https://doi.org/10.3390/jmp3020010

12/11/2025

⏱️ Delayed or limited access to molecular testing results such as MSI/MMR can lead to patient anxiety, suboptimal treatment decisions and disparities in outcomes*.

💡 Real-world evidence has demonstrated that 𝗺𝗼𝗹𝗲𝗰𝘂𝗹𝗮𝗿 𝗠𝗦𝗜 is a 𝗯𝗲𝘁𝘁𝗲𝗿 𝘁𝗲𝘀𝘁𝗶𝗻𝗴 𝗺𝗲𝘁𝗵𝗼𝗱 than IHC to predict 𝗧𝗧𝗡𝗧, 𝗣𝗙𝗦 𝗮𝗻𝗱 𝗢𝗦 𝘄𝗶𝘁𝗵 𝗜𝗖𝗜**.

👉 The 𝗜𝗱𝘆𝗹𝗹𝗮™ 𝗖𝗗𝘅 𝗠𝗦𝗜 𝗧𝗲𝘀𝘁 is a fast testing solution that fits any hospital setting, helping overcome testing barriers, support equitable care and ensure optimal CRC patient outcomes. 𝗟𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲: https://www.biocartis.com/en-US/meet-idylla/idylla-oncology-assays/idylla-cdx-msi-test

Approved in the US under P250005.
* https://lnkd.in/eY-PFkY3; https://lnkd.in/eWkNDvBe; https://lnkd.in/eEur9VdG
** https://lnkd.in/eMj53Dcw

10/11/2025

💙 𝐘𝐨𝐮𝐫 𝐏𝐚𝐭𝐢𝐞𝐧𝐭𝐬, 𝐎𝐮𝐫 𝐏𝐫𝐢𝐨𝐫𝐢𝐭𝐲

This 𝐋𝐮𝐧𝐠 𝐂𝐚𝐧𝐜𝐞𝐫 𝐀𝐰𝐚𝐫𝐞𝐧𝐞𝐬𝐬 𝐌𝐨𝐧𝐭𝐡, we're highlighting that 𝐥𝐨𝐧𝐠 𝐰𝐚𝐢𝐭𝐢𝐧𝐠 𝐩𝐞𝐫𝐢𝐨𝐝𝐬 for biomarker results can 𝐝𝐞𝐥𝐚𝐲 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐝𝐞𝐜𝐢𝐬𝐢𝐨𝐧𝐬 for NSCLC patients. Advanced NSCLC patients often 𝐫𝐚𝐩𝐢𝐝𝐥𝐲 𝐝𝐞𝐭𝐞𝐫𝐢𝐨𝐫𝐚𝐭𝐞 𝐨𝐫 𝐫𝐞𝐜𝐞𝐢𝐯𝐞 𝐬𝐮𝐛-𝐨𝐩𝐭𝐢𝐦𝐚𝐥 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 while waiting for their biomarker results.

According to the 𝐈𝐀𝐒𝐋𝐂 𝟐𝟎𝟐𝟒 𝐆𝐥𝐨𝐛𝐚𝐥 𝐒𝐮𝐫𝐯𝐞𝐲, 𝟒𝟑% of respondents sometimes or often treat patients before receiving biomarker results due to barriers such as cost, turnaround time, and sample quality. 📊 But data show it matters: Aggarwal et al. (2023) demonstrated that patients with biomarker results available 𝐛𝐞𝐟𝐨𝐫𝐞 𝟏𝐋 𝐭𝐡𝐞𝐫𝐚𝐩𝐲 achieve 𝐛𝐞𝐭𝐭𝐞𝐫 𝐨𝐯𝐞𝐫𝐚𝐥𝐥 𝐬𝐮𝐫𝐯𝐢𝐯𝐚𝐥 compared to those without.

⏱️ The 𝐈𝐝𝐲𝐥𝐥𝐚™ 𝐋𝐮𝐧𝐠 𝐂𝐚𝐧𝐜𝐞𝐫 𝐏𝐨𝐫𝐭𝐟𝐨𝐥𝐢𝐨 helps overcome these barriers — delivering results for key biomarkers (𝐄𝐆𝐅𝐑, 𝐀𝐋𝐊, 𝐑𝐎𝐒𝟏, 𝐑𝐄𝐓, 𝐌𝐄𝐓𝐞𝐱𝟏𝟒) in 𝐨𝐧𝐥𝐲 𝟑 𝐡𝐨𝐮𝐫𝐬, so clinicians can start the right targeted 1L therapy immediately for >90% of NSCLC patients.

🔍 Learn more: https://www.biocartis.com/en/idylla-for-lung-cancer?utm_source=facebook&utm_medium=social&utm_campaign=1011_idylla-for-lung-cancer

Idylla™ GeneFusion Panel and Idylla™ EGFR Mutation Test are CE-marked in Europe and approved in many other countries, but are for Research Use Only (RUO), not for use in diagnostic procedures in the US.
Aggarwal, C. et al (2023). Association Between Availability of Molecular Genotyping Results and Overall Survival in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer. JCO precision oncology, 7. https://doi.org/10.1200/PO.23.00191

07/11/2025

💡 𝗝𝗼𝗶𝗻 𝗼𝘂𝗿 𝗔𝗠𝗣 𝘄𝗼𝗿𝗸𝘀𝗵𝗼𝗽: 𝘍𝘢𝘴𝘵 𝘌𝘎𝘍𝘙 𝘛𝘦𝘴𝘵𝘪𝘯𝘨 𝘪𝘯 𝘊𝘺𝘵𝘰𝘱𝘢𝘵𝘩𝘰𝘭𝘰𝘨𝘺: 𝘈 𝘗𝘳𝘢𝘤𝘵𝘪𝘤𝘢𝘭 𝘐𝘮𝘱𝘭𝘦𝘮𝘦𝘯𝘵𝘢𝘵𝘪𝘰𝘯 𝘌𝘹𝘱𝘦𝘳𝘪𝘦𝘯𝘤𝘦
🗣️ Dr. Roberto Ruiz-Cordero (University of Miami)
🗓️ 12 November, 03:00 PM (EST)
📍 AMP 2025, Boston Convention & Exhibition Center, 156AB, level 1

Dr. Ruiz-Cordero will present results from the 𝗽𝗿𝗼𝘀𝗽𝗲𝗰𝘁𝗶𝘃𝗲 𝗙𝗔𝗖𝗜𝗟𝗜𝗧𝗔𝗧𝗘 𝘀𝘁𝘂𝗱𝘆 exploring how Idylla™ can 𝗰𝗼𝗺𝗽𝗹𝗲𝗺𝗲𝗻𝘁 𝗡𝗚𝗦 for EGFR testing in 𝗹𝘂𝗻𝗴 𝗰𝗮𝗻𝗰𝗲𝗿 tissue and 𝗰𝘆𝘁𝗼𝗹𝗼𝗴𝘆 𝘀𝗮𝗺𝗽𝗹𝗲𝘀 with 𝗺𝗶𝗻𝗶𝗺𝗮𝗹 𝘀𝗮𝗺𝗽𝗹𝗲 𝗶𝗻𝗽𝘂𝘁. Learn how fast molecular testing can help...
✅ Rescue Quantity Non Sufficient (QNS) NGS cases
✅ Reduce turnaround time
✅ Accelerate decisions
Join the workshop and gain practical insights into 𝗿𝗲𝗮𝗹-𝘄𝗼𝗿𝗹𝗱 𝗶𝗺𝗽𝗹𝗲𝗺𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻 of EGFR testing in the cytopathology lab!

Be sure to also visit us at 𝗯𝗼𝗼𝘁𝗵 𝟰𝟮𝟭!
👉 𝗕𝗼𝗼𝗸 𝘆𝗼𝘂𝗿 𝗺𝗲𝗲𝘁𝗶𝗻𝗴: https://www.biocartis.com/en-US/news-events/events/amp
👉 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿 𝗜𝗱𝘆𝗹𝗹𝗮™: https://www.biocartis.com/en-US/meet-idylla

We can’t wait to connect with you in Boston! 👋

Idylla™ EGFR Mutation Assay is for Research Use Only (RUO), not for use in diagnostic procedures.

05/11/2025

📢 𝗡𝗢𝗪 𝗔𝗩𝗔𝗜𝗟𝗔𝗕𝗟𝗘: 𝗜𝗱𝘆𝗹𝗹𝗮™ 𝗖𝗗𝘅 𝗠𝗦𝗜 𝗧𝗲𝘀𝘁
For the identification of MSI-H CRC patients who may benefit from treatment with 𝗢𝗣𝗗𝗜𝗩𝗢® (nivolumab) ± 𝗬𝗘𝗥𝗩𝗢𝗬® (ipilimumab)
✔️ 𝗖𝗼𝗺𝗽𝗮𝗻𝗶𝗼𝗻 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰 for standardized MSI-H and MSS detection in CRC
✔️ Sample to result in approximately 𝟭𝟱𝟬 𝗺𝗶𝗻𝘂𝘁𝗲𝘀 without the need for sample batching
✔️ Concordance rate of 𝟵𝟴.𝟱𝟳% against OncoMate™ MSI Dx Analysis System
✔️ Directly from 𝗙𝗙𝗣𝗘 𝘁𝗶𝘀𝘀𝘂𝗲, no paired tissue samples needed

👉 𝗟𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲: https://www.biocartis.com/en-US/meet-idylla/idylla-oncology-assays/idylla-cdx-msi-test

Approved in the US under P250005. OPDIVO® and YERVOY® are registered trademarks of Bristol Myers Squibb Company.

03/11/2025

November is Lung Cancer Awareness Month 🤍🫁

💡 Did you know that lung cancer is the most common type of cancer and the leading cause of cancer deaths worldwide? Since lung cancer can progress rapidly, early detection and prompt treatment are crucial for patients ⏳
Idylla™ allows for fast & accurate results of key NSCLC gene mutations and fusions in ⏱️ONLY 3 HOURS⏱️, speeding up therapy decisions for better patient outcomes.

Learn more 👀 https://www.biocartis.com/en/idylla-for-lung-cancer?utm_source=facebook&utm_medium=social&utm_campaign=0311_idylla-for-lung-cancer

31/10/2025

🎃 Trick or treat?
This Halloween, we’re skipping the tricks and going straight to the treats.

🍬 Our treat: Molecular biomarker results in only 3 hours with Idylla™
https://www.biocartis.com/en/meet-idylla?utm_source=facebook&utm_medium=social&utm_campaign=3110_meet-idylla

Happy Halloween from all of us at Biocartis! 👻🧬

29/10/2025

💡 Early detection and prompt treatment are crucial for lung cancer patients
Test for EGFR, ALK, ROS1, RET and METex14 in ONLY 3 HOURS and immediately start the right targeted therapy for >90% of your patients with first-line actionable biomarkers*.

IDYLLA™ FIRST. Guiding First-Line Therapy Decisions in NSCLC ⏱️

Learn more 👉🏻https://www.biocartis.com/sites/default/files/2025-06/idylla_first-line_lung_1l_-_leaflet_-_may2025.pdf

*Hendriks, L. E., et al. (2023). Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 34(4), 339–357.

28/10/2025

𝗡𝗲𝘅𝘁 𝘄𝗲𝗲𝗸 𝘄𝗲 𝗮𝗿𝗲 𝗮𝘁𝘁𝗲𝗻𝗱𝗶𝗻𝗴 𝗣𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆 & 𝗗𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰𝘀 𝟮𝟬𝟮𝟱 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲!
📅 5-6 November | 🗺️ New York, NY, US

Stop by and learn more about getting molecular biomarker results in ⏱️only 3 hours⏱️ with Idylla™!
👉 𝗕𝗼𝗼𝗸 𝘆𝗼𝘂𝗿 𝗺𝗲𝗲𝘁𝗶𝗻𝗴: https://lnkd.in/eRxYe3YF
👉 𝗟𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲: https://lnkd.in/eRx8fbYs

27/10/2025

𝗠𝗮𝗿𝗸 𝘆𝗼𝘂𝗿 𝗰𝗮𝗹𝗲𝗻𝗱𝗮𝗿𝘀 𝗳𝗼𝗿 𝗔𝗠𝗣!
🗓️ 11-15 November |📍Boston, MA, US

Visit us at 𝗯𝗼𝗼𝘁𝗵 𝟰𝟮𝟭 and discover how Idylla™ can deliver your fully automated molecular biomarker results in 𝗼𝗻𝗹𝘆 𝟯 𝗵𝗼𝘂𝗿𝘀!
👉 𝗕𝗼𝗼𝗸 𝘆𝗼𝘂𝗿 𝗺𝗲𝗲𝘁𝗶𝗻𝗴: https://www.biocartis.com/en-US/news-events/events/amp
👉 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿 𝗜𝗱𝘆𝗹𝗹𝗮™: https://www.biocartis.com/en-US/meet-idylla

𝗗𝗼𝗻'𝘁 𝗺𝗶𝘀𝘀 𝗼𝘂𝗿 𝗔𝗠𝗣 𝘄𝗼𝗿𝗸𝘀𝗵𝗼𝗽: 𝘍𝘢𝘴𝘵 𝘌𝘎𝘍𝘙 𝘛𝘦𝘴𝘵𝘪𝘯𝘨 𝘪𝘯 𝘊𝘺𝘵𝘰𝘱𝘢𝘵𝘩𝘰𝘭𝘰𝘨𝘺: 𝘈 𝘗𝘳𝘢𝘤𝘵𝘪𝘤𝘢𝘭 𝘐𝘮𝘱𝘭𝘦𝘮𝘦𝘯𝘵𝘢𝘵𝘪𝘰𝘯 𝘌𝘹𝘱𝘦𝘳𝘪𝘦𝘯𝘤𝘦, hosted by Dr. Roberto Ruiz-Cordero (University of Miami).
🗓️ 12 November, 03:00 PM (EST) | 📍 156AB, level 1

We can’t wait to connect with you in Boston! 👋

Adres

Generaal De Wittelaan 11B
Mechelen
2800

Telefoon

+3215632600

Website

http://www.biocartis.com/

Meldingen

Wees de eerste die het weet en laat ons u een e-mail sturen wanneer Biocartis nieuws en promoties plaatst. Uw e-mailadres wordt niet voor andere doeleinden gebruikt en u kunt zich op elk gewenst moment afmelden.